Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Jeffrey Montgomery to Prostatic Neoplasms

This is a "connection" page, showing publications Jeffrey Montgomery has written about Prostatic Neoplasms.

 
Connection Strength
  
 
 
5.047
  
  1. Montgomery JS. Prostate cancer: Patient-reported functional outcomes with radiation therapy. Nat Rev Urol. 2010 Oct; 7(10):537-8.
    View in: PubMed
    Score: 0.271
  2. Montgomery JS, Gayed BA, Hollenbeck BK, Daignault S, Sanda MG, Montie JE, Wei JT. Obesity adversely affects health related quality of life before and after radical retropubic prostatectomy. J Urol. 2006 Jul; 176(1):257-61; discussion 261-2.
    View in: PubMed
    Score: 0.202
  3. Hu JC, Assel M, Allaf ME, Ehdaie B, Vickers AJ, Cohen AJ, Ristau BT, Green DA, Han M, Rezaee ME, Pavlovich CP, Montgomery JS, Kowalczyk KJ, Ross AE, Kundu SD, Patel HD, Wang GJ, Graham JN, Shoag JE, Ghazi A, Singla N, Gorin MA, Schaeffer AJ, Schaeffer EM. Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol. 2024 Jul; 86(1):61-68.
    View in: PubMed
    Score: 0.170
  4. Singhal U, Hollenbeck BK, Kaffenberger SD, Salami SS, George AK, Skolarus TA, Montgomery JS, Wittmann DA, Miller DC, Wei JT, Palapattu GS, Montie JE, Dunn RL, Morgan TM. Comparing Patient-reported Functional Outcomes After Radical Prostatectomy in Historical and Contemporary Practice. J Urol. 2023 Nov; 210(5):771-777.
    View in: PubMed
    Score: 0.165
  5. Hu J, Zhu A, Vickers A, Allaf ME, Ehdaie B, Schaeffer A, Pavlovich C, Ross AE, Green DA, Wang G, Ginzburg S, Montgomery JS, George A, Graham JN, Ristau BT, Correa A, Shoag JE, Kowalczyk KJ, Zhang TR, Schaeffer EM. Protocol of a multicentre randomised controlled trial assessing transperineal prostate biopsy to reduce infectiouscomplications. BMJ Open. 2023 05 19; 13(5):e071191.
    View in: PubMed
    Score: 0.163
  6. Dhir A, Ellimoottil CS, Qi J, Zhu A, Wang RS, Montgomery JS, Salami SS, Wei JT, Shankar PR, Davenport MS, Curci NE, Millet JD, Wu CY, Johnson A, Miller DC, George AK. Intra-practice Urologist-level Variation in Targeted Fusion Biopsy Outcomes. Urology. 2023 07; 177:122-127.
    View in: PubMed
    Score: 0.162
  7. Hammer L, Jiang R, Hearn J, Lashbrook J, Mitchell A, Daignault-Newton S, Dess RT, Jackson WC, Reichert Z, Alumkal JJ, Kaffenberger S, George A, Montgomery J, Salami SS, Morgan TM, Miller D, Wittman D, Hollenbeck B, Mehra R, Davenport MS, Sun Y, Schipper M, Palapattu G, Spratt DE. A Phase I Trial of Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for Locally Advanced Prostate Cancer. Int J Radiat Oncol Biol Phys. 2023 01 01; 115(1):132-141.
    View in: PubMed
    Score: 0.154
  8. Tosoian JJ, Singhal U, Davenport MS, Wei JT, Montgomery JS, George AK, Salami SS, Mukundi SG, Siddiqui J, Kunju LP, Tooke BP, Ryder CY, Dugan SP, Chopra Z, Botbyl R, Feng Y, Sessine MS, Eyrich NW, Ross AE, Trock BJ, Tomlins SA, Palapattu GS, Chinnaiyan AM, Niknafs YS, Morgan TM. Urinary MyProstateScore (MPS) to Rule out Clinically-Significant Cancer in Men with Equivocal (PI-RADS 3) Multiparametric MRI: Addressing an Unmet Clinical Need. Urology. 2022 06; 164:184-190.
    View in: PubMed
    Score: 0.147
  9. Stensland KD, Kaffenberger SD, George AK, Morgan TM, Miller DC, Salami SS, Dunn RL, Palapattu GS, Montgomery JS, Hollenbeck BK, Skolarus TA. Prostate cancer clinical trial completion: The role of geography. Contemp Clin Trials. 2021 12; 111:106600.
    View in: PubMed
    Score: 0.146
  10. Abghari-Gerst M, Armstrong WR, Nguyen K, Calais J, Czernin J, Lin D, Jariwala N, Rodnick M, Hope TA, Hearn J, Montgomery JS, Alva A, Reichert ZR, Spratt DE, Johnson TD, Scott PJH, Piert M. A Comprehensive Assessment of 68Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients. J Nucl Med. 2022 04; 63(4):567-572.
    View in: PubMed
    Score: 0.144
  11. Abdulfatah E, Reichert ZR, Davenport MS, Chinnaiyan AM, Dadhania V, Wang X, Mannan R, Kunju LP, Hollenbeck BK, Montgomery JS, Kaffenberger SD, Morgan TM, Alva AS, Palapattu GS, Vaishampayan UN, Alumkal JJ, Spratt DE, Udager AM, Mehra R. De novo neuroendocrine transdifferentiation in primary prostate cancer-a phenotype associated with advanced clinico-pathologic features and aggressive outcome. Med Oncol. 2021 Feb 14; 38(3):26.
    View in: PubMed
    Score: 0.139
  12. Peabody H, Lane BR, Qi J, Kim T, Montie JE, Moriarity A, Brede CM, Montgomery J. Limitations of abdominopelvic CT and multiparametric MR imaging for detection of lymph node metastases prior to radical prostatectomy. World J Urol. 2021 Mar; 39(3):779-785.
    View in: PubMed
    Score: 0.132
  13. Gross MD, Sedrakyan A, Bianco FJ, Carroll PR, Daskivich TJ, Eggener SE, Ehdaie B, Fisher B, Gorin MA, Hunt B, Jiang H, Klein EA, Marinac-Dabic D, Montgomery JS, Polascik TJ, Priester AM, Rastinehad AR, Viviano CJ, Wysock JS, Hu JC. SPARED Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer. J Urol. 2019 11; 202(5):952-958.
    View in: PubMed
    Score: 0.127
  14. Gross MD, Sedrakyan A, Bianco FJ, Carroll PR, Daskivich TJ, Eggener SE, Ehdaie B, Fisher B, Gorin MA, Hunt B, Jiang H, Klein EA, Marinac-Dabic D, Montgomery JS, Polascik TJ, Priester AM, Rastinehad AR, Viviano CJ, Wysock JS, Hu JC. Reply by Authors. J Urol. 2019 11; 202(5):958.
    View in: PubMed
    Score: 0.127
  15. Mannan R, Taylor AS, Spratt DE, Chinnaiyan AM, Montgomery JS, Brown NA, Mehra R. TERT- beyond the territory: Usage of PCR-based TERT promoter assay in defining urothelial carcinoma in a case of long-standing prostatic adenocarcinoma. Pathol Res Pract. 2020 Jan; 216(1):152663.
    View in: PubMed
    Score: 0.126
  16. Davenport MS, Montgomery JS, Kunju LP, Siddiqui J, Shankar PR, Rajendiran T, Shao X, Lee E, Denton B, Barnett C, Piert M. 18F-Choline PET/mpMRI for Detection of Clinically Significant Prostate Cancer: Part 1. Improved Risk Stratification for MRI-Guided Transrectal Prostate Biopsies. J Nucl Med. 2020 03; 61(3):337-343.
    View in: PubMed
    Score: 0.126
  17. Barnett CL, Davenport MS, Montgomery JS, Kunju LP, Denton BT, Piert M. 18F-Choline PET/mpMRI for Detection of Clinically Significant Prostate Cancer: Part 2. Cost-Effectiveness Analysis. J Nucl Med. 2019 12; 60(12):1705-1712.
    View in: PubMed
    Score: 0.125
  18. Shankar PR, Maturen KE, George AK, Borza T, Ellimoottil C, Montgomery JS, Wei JT, Denton BT, Davenport MS. Temporary Health Impact of Prostate MRI and Transrectal Prostate Biopsy in Active Surveillance Prostate Cancer Patients. J Am Coll Radiol. 2019 Oct; 16(10):1385-1392.
    View in: PubMed
    Score: 0.121
  19. Curci NE, Gartland P, Shankar PR, Montgomery JS, Miller DC, George AK, Davenport MS. Long-distance longitudinal prostate MRI quality assurance: from startup to 12 months. Abdom Radiol (NY). 2018 09; 43(9):2505-2512.
    View in: PubMed
    Score: 0.117
  20. Curci NE, Lane BR, Shankar PR, Noyes SL, Moriarity AK, Kubat A, Brede C, Montgomery JS, Auffenberg GB, Miller DC, Montie JE, George AK, Davenport MS. Integration and Diagnostic Accuracy of 3T Nonendorectal coil Prostate Magnetic Resonance Imaging in the Context of Active Surveillance. Urology. 2018 06; 116:137-143.
    View in: PubMed
    Score: 0.114
  21. Barnett CL, Davenport MS, Montgomery JS, Wei JT, Montie JE, Denton BT. Cost-effectiveness of magnetic resonance imaging and targeted fusion biopsy for early detection of prostate cancer. BJU Int. 2018 07; 122(1):50-58.
    View in: PubMed
    Score: 0.114
  22. Golan R, Bernstein A, Sedrakyan A, Daskivich TJ, Du DT, Ehdaie B, Fisher B, Gorin MA, Grunberger I, Hunt B, Jiang HH, Kim HL, Marinac-Dabic D, Marks LS, McClure TD, Montgomery JS, Parekh DJ, Punnen S, Scionti S, Viviano CJ, Wei JT, Wenske S, Wysock JS, Rewcastle J, Carol M, Oczachowski M, Hu JC. Development of a Nationally Representative Coordinated Registry Network for Prostate Ablation Technologies. J Urol. 2018 06; 199(6):1488-1493.
    View in: PubMed
    Score: 0.112
  23. Gilbert SM, Dunn RL, Miller DC, Montgomery JS, Skolarus TA, Weizer AZ, Wood DP, Hollenbeck BK. Functional Outcomes Following Nerve Sparing Prostatectomy Augmented with Seminal Vesicle Sparing Compared to Standard Nerve Sparing Prostatectomy: Results from a Randomized Controlled Trial. J Urol. 2017 09; 198(3):600-607.
    View in: PubMed
    Score: 0.107
  24. Piert M, Shao X, Raffel D, Davenport MS, Montgomery J, Kunju LP, Hockley BG, Siddiqui J, Scott PJH, Chinnaiyan AM, Rajendiran T. Preclinical Evaluation of 11C-Sarcosine as a Substrate of Proton-Coupled Amino Acid Transporters and First Human Application in Prostate Cancer. J Nucl Med. 2017 08; 58(8):1216-1223.
    View in: PubMed
    Score: 0.106
  25. Jackson WC, Desai NB, Abugharib AE, Tumati V, Dess RT, Lee JY, Zhao SG, Soliman M, Folkert M, Laine A, Hannan R, Zumsteg ZS, Sandler H, Hamstra DA, Montgomery JS, Miller DC, Kozminski MA, Hollenbeck BK, Hearn JW, Palapattu G, Tomlins SA, Mehra R, Morgan TM, Feng FY, Spratt DE. Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study. BJU Int. 2017 09; 120(3):351-357.
    View in: PubMed
    Score: 0.106
  26. Hussein AA, Ghani KR, Peabody J, Sarle R, Abaza R, Eun D, Hu J, Fumo M, Lane B, Montgomery JS, Hinata N, Rooney D, Comstock B, Chan HK, Mane SS, Mohler JL, Wilding G, Miller D, Guru KA. Development and Validation of an Objective Scoring Tool for Robot-Assisted Radical Prostatectomy: Prostatectomy Assessment and Competency Evaluation. J Urol. 2017 05; 197(5):1237-1244.
    View in: PubMed
    Score: 0.104
  27. Scherr KA, Fagerlin A, Hofer T, Scherer LD, Holmes-Rovner M, Williamson LD, Kahn VC, Montgomery JS, Greene KL, Zhang B, Ubel PA. Physician Recommendations Trump Patient Preferences in Prostate Cancer Treatment Decisions. Med Decis Making. 2017 01; 37(1):56-69.
    View in: PubMed
    Score: 0.102
  28. Kozminski MA, Tomlins S, Cole A, Singhal U, Lu L, Skolarus TA, Palapattu GS, Montgomery JS, Weizer AZ, Mehra R, Hollenbeck BK, Miller DC, He C, Feng FY, Morgan TM. Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy. Urol Oncol. 2016 09; 34(9):415.e1-6.
    View in: PubMed
    Score: 0.100
  29. Spratt DE, Cole AI, Palapattu GS, Weizer AZ, Jackson WC, Montgomery JS, Dess RT, Zhao SG, Lee JY, Wu A, Kunju LP, Talmich E, Miller DC, Hollenbeck BK, Tomlins SA, Feng FY, Mehra R, Morgan TM. Independent surgical validation of the new prostate cancer grade-grouping system. BJU Int. 2016 Nov; 118(5):763-769.
    View in: PubMed
    Score: 0.100
  30. Piert M, Montgomery J, Kunju LP, Siddiqui J, Rogers V, Rajendiran T, Johnson TD, Shao X, Davenport MS. 18F-Choline PET/MRI: The Additional Value of PET for MRI-Guided Transrectal Prostate Biopsies. J Nucl Med. 2016 Jul; 57(7):1065-70.
    View in: PubMed
    Score: 0.099
  31. Cole AI, Morgan TM, Spratt DE, Palapattu GS, He C, Tomlins SA, Weizer AZ, Feng FY, Wu A, Siddiqui J, Chinnaiyan AM, Montgomery JS, Kunju LP, Miller DC, Hollenbeck BK, Wei JT, Mehra R. Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence. J Urol. 2016 08; 196(2):405-11.
    View in: PubMed
    Score: 0.099
  32. Magers MJ, Zhan T, Udager AM, Wei JT, Tomlins SA, Wu AJ, Kunju LP, Lew M, Feng FY, Hamstra DA, Siddiqui J, Chinnaiyan AM, Montgomery JS, Weizer AZ, Morgan TM, Hollenbeck BK, Miller DC, Palapattu GS, Jiang H, Mehra R. Clinicopathologic characteristics of anterior prostate cancer (APC), including correlation with previous biopsy pathology. Med Oncol. 2015 Nov; 32(11):249.
    View in: PubMed
    Score: 0.096
  33. Holmes-Rovner M, Montgomery JS, Rovner DR, Scherer LD, Whitfield J, Kahn VC, Merkle EC, Ubel PA, Fagerlin A. Informed Decision Making: Assessment of the Quality of Physician Communication about Prostate Cancer Diagnosis and Treatment. Med Decis Making. 2015 11; 35(8):999-1009.
    View in: PubMed
    Score: 0.095
  34. Gilbert SM, Dunn RL, Wittmann D, Montgomery JS, Hollingsworth JM, Miller DC, Hollenbeck BK, Wei JT, Montie JE. Quality of life and satisfaction among prostate cancer patients followed in a dedicated survivorship clinic. Cancer. 2015 May 01; 121(9):1484-91.
    View in: PubMed
    Score: 0.091
  35. Kozminski MA, Palapattu GS, Mehra R, Montgomery JS, Weizer AZ, Skolarus TA, Hollenbeck BK, Miller DC, He C, Tomlins S, Montie JE, Feng FY, Wood DP, Kunju LP, Morgan TM. Understanding the relationship between tumor size, gland size, and disease aggressiveness in men with prostate cancer. Urology. 2014 Aug; 84(2):373-8.
    View in: PubMed
    Score: 0.088
  36. Schroeck FR, Kaufman SR, Jacobs BL, Skolarus TA, Miller DC, Montgomery JS, Weizer AZ, Hollenbeck BK. Adherence to performance measures and outcomes among men treated for prostate cancer. J Urol. 2014 Sep; 192(3):743-8.
    View in: PubMed
    Score: 0.086
  37. Schroeck FR, Kaufman SR, Jacobs BL, Zhang Y, Weizer AZ, Montgomery JS, Gilbert SM, Strope SA, Hollenbeck BK. The impact of technology diffusion on treatment for prostate cancer. Med Care. 2013 Dec; 51(12):1076-84.
    View in: PubMed
    Score: 0.085
  38. Schroeck FR, Kaufman SR, Jacobs BL, Skolarus TA, Miller DC, Weizer AZ, Montgomery JS, Wei JT, Shahinian VB, Hollenbeck BK. Technology diffusion and diagnostic testing for prostate cancer. J Urol. 2013 Nov; 190(5):1715-20.
    View in: PubMed
    Score: 0.081
  39. DeLancey JO, Wood DP, He C, Montgomery JS, Weizer AZ, Miller DC, Jacobs BL, Montie JE, Hollenbeck BK, Skolarus TA. Evidence of perineural invasion on prostate biopsy specimen and survival after radical prostatectomy. Urology. 2013 Feb; 81(2):354-7.
    View in: PubMed
    Score: 0.080
  40. Jacobs BL, Montgomery JS, Dunn RL, Weizer AZ, Miller DC, Wood DP, Wolf JS, Zhang Y, Wei JT, Hollenbeck BK. A comparison of extraperitoneal and intraperitoneal approaches for robotic prostatectomy. Surg Innov. 2012 Sep; 19(3):268-74.
    View in: PubMed
    Score: 0.074
  41. Skolarus TA, Hedgepeth RC, Zhang Y, Weizer AZ, Montgomery JS, Miller DC, Wood DP, Hollenbeck BK. Does robotic technology mitigate the challenges of large prostate size? Urology. 2010 Nov; 76(5):1117-21.
    View in: PubMed
    Score: 0.067
  42. Bennett CL, Price DK, Kim S, Liu D, Jovanovic BD, Nathan D, Johnson ME, Montgomery JS, Cude K, Brockbank JC, Sartor O, Figg WD. Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. J Clin Oncol. 2002 Sep 01; 20(17):3599-604.
    View in: PubMed
    Score: 0.039
  43. Cude KJ, Montgomery JS, Price DK, Dixon SC, Kincaid RL, Kovacs KF, Venzon DJ, Liewehr DJ, Johnson ME, Reed E, Figg WD. The role of an androgen receptor polymorphism in the clinical outcome of patients with metastatic prostate cancer. Urol Int. 2002; 68(1):16-23.
    View in: PubMed
    Score: 0.037
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.